Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Metastatic spinal cord compression

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Spinal cord or cauda-equina compression

New limb weakness, sensory change, gait disturbance or bladder or bowel dysfunction in a person with current, previous or suspected cancer is an oncological emergency.

Action: Contact the local metastatic spinal cord compression coordinator immediately, protect the spine according to pain and stability, give dexamethasone 16 mg promptly when neurological symptoms or signs are present, and obtain urgent MRI of the whole spine within 24 hours to direct surgery or radiotherapy.

Synopsis

Recognise cord or cauda-equina compromise before irreversible neurological loss, protect the spine, obtain whole-spine MRI within the emergency window and coordinate definitive surgery, radiotherapy and cancer care.

  • MSCC is cord or cauda-equina compression by epidural tumour, vertebral collapse or pathological fracture; neurological function at definitive treatment is the strongest practical predictor of recovery.
  • Key symptoms are severe progressive spinal or radicular pain, pain on movement or strain, weakness, gait change, sensory loss and new bladder or bowel dysfunction.
  • Contact the named MSCC pathway immediately; do not send a patient with neurological signs through a routine back-pain or outpatient cancer referral.
  • Gold-standard imaging is MRI of the whole spine, performed as soon as possible and always within 24 hours for suspected MSCC; do not use plain radiographs to exclude it.
  • If neurological symptoms or signs are present, give dexamethasone 16 mg orally or equivalent parenteral dose as soon as possible, then continue 16 mg daily while awaiting surgery or radiotherapy under NICE.
  • Protect movement when pain suggests instability, but individualise lying flat, log rolling and mobilisation to pain, respiratory risk and specialist stability assessment.
  • Definitive management is urgent spinal surgery with stabilisation for selected fit patients when decompression and stability offer benefit, or urgent radiotherapy when surgery is unsuitable.
  • Start rehabilitation, bladder and bowel care, pressure-area protection, thrombosis assessment and realistic goals early rather than waiting for oncological treatment to finish.

Key red flags

Progressive bilateral or unilateral limb weakness, gait failure or falls with spinal pain requires emergency MSCC assessment.

A sensory level, saddle sensory loss, urinary retention, overflow, faecal incontinence or reduced anal function suggests cord or cauda-equina compromise.

Severe unremitting spinal pain, night pain, pain worsened by movement, cough or strain, or new radicular pain in cancer is suspicious even before deficit.

Rapidly increasing mechanical pain on sitting, standing or turning suggests instability and requires protected movement and specialist review.

Normal plain radiographs or an old reassuring scan do not exclude epidural disease at another spinal level.

Cord motor syndrome

Heavy legs, focal weakness, spasticity, hyperreflexia, extensor plantar responses, poor balance or inability to walk indicates long-tract compromise.

Sensory pathway change

Numbness, paraesthesia, a truncal sensory level or saddle loss may be subtle and should be mapped and documented before transfer.

Autonomic dysfunction

New hesitancy, retention, overflow, incontinence, constipation, faecal loss or sexual dysfunction indicates cord or cauda-equina involvement.

Investigation priorities

01
Gold-standard whole-spine MRIFirst step

Confirm compression, level, number of lesions, neural signal and vertebral or epidural anatomy for definitive planning.

Management branches

SuspectActivate the MSCC pathway

Cancer coexists with suspicious spinal pain, neurological symptom or sphincter change.

  1. Contact the named MSCC coordinator or on-call oncology and spinal service immediately and communicate time of onset, walking status, neurological findings, pain and current cancer treatment.
  2. Assess ABCDE, give analgesia, map motor, sensory and bladder function and protect the spine when movement-provoked pain or instability is suspected.
  3. Give dexamethasone promptly for neurological symptoms or signs and arrange whole-spine MRI as soon as possible and within 24 hours.

Key medicines

Dexamethasone for neurological MSCCGive dexamethasone 16 mg orally, or an equivalent parenteral dose, as soon as possible when neurological symptoms or signs are present, then continue 16 mg daily while awaiting surgery or radiotherapy before a specialist-guided taper.Monitor glucose, infection, delirium, proximal weakness, gastrointestinal risk and sleep. Do not use routine high-dose steroid in every asymptomatic vertebral metastasis; if MSCC is excluded, stop or taper according to exposure and adrenal risk.
Opioid analgesiaFor severe pain in an opioid-naive adult, a common starting approach is immediate-release oral morphine 2.5 to 5 mg every 4 hours with the same dose available for breakthrough, titrated to response and renal function.Prescribe laxative and antiemetic when indicated, monitor sedation and respiration and select an alternative in significant renal impairment; analgesic response never excludes instability or compression.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG234 spinal metastases and MSCCRecognition, 24-hour MRI, corticosteroids, stability, surgery, radiotherapy and rehabilitation.
  • NICE NG234 information for the publicUrgent symptoms, pathway expectations and shared decisions.
  • NICE BNF dexamethasoneUK corticosteroid contraindications, interactions and adverse-effect monitoring.
  • NICE NG89 venous thromboembolism preventionRisk assessment and prophylaxis during cancer-related hospital immobility.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom